RadNet Inc. (NASDAQ:RDNT) VP Mark Stolper sold 20,703 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $15.15, for a total transaction of $313,650.45. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of RDNT opened at $15.10 on Friday. The company has a 50-day simple moving average of $14.49 and a 200-day simple moving average of $13.51. The company has a quick ratio of 0.72, a current ratio of 0.80 and a debt-to-equity ratio of 5.09. The company has a market capitalization of $753.91 million, a PE ratio of 22.88, a P/E/G ratio of 6.08 and a beta of 1.02. RadNet Inc. has a 52-week low of $9.97 and a 52-week high of $16.54.
RadNet (NASDAQ:RDNT) last announced its quarterly earnings results on Thursday, August 8th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.02). The company had revenue of $289.10 million during the quarter, compared to analysts’ expectations of $272.36 million. RadNet had a net margin of 3.33% and a return on equity of 18.91%. The business’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.11 EPS. On average, research analysts anticipate that RadNet Inc. will post 0.33 EPS for the current year.
RDNT has been the subject of a number of analyst reports. BidaskClub upgraded shares of RadNet from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Zacks Investment Research downgraded shares of RadNet from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, TheStreet downgraded shares of RadNet from a “b-” rating to a “c” rating in a report on Tuesday, June 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. RadNet has a consensus rating of “Buy” and a consensus price target of $17.75.
RadNet Company Profile
RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.
Further Reading: How Investors Can Profit from Options Trading
Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.